These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31590236)

  • 21. Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study.
    Razali K; Mohd Nasir MH; Othman N; Doolaanea AA; Kumar J; Nabeel Ibrahim W; Mohamed WMY
    PLoS One; 2022; 17(10):e0274844. PubMed ID: 36190968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
    Wang YS; Zhou JP; Wei ZF; Tian QY; Zhou HX; Zhang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1199-202, 1205. PubMed ID: 17715026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease.
    Peoples C; Spana S; Ashkan K; Benabid AL; Stone J; Baker GE; Mitrofanis J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):469-76. PubMed ID: 22285756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.
    Zhao C; Ling Z; Newman MB; Bhatia A; Carvey PM
    Neurobiol Dis; 2007 Apr; 26(1):36-46. PubMed ID: 17234424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
    Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
    Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
    Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
    Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
    Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
    Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
    FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
    Shchepinov MS; Chou VP; Pollock E; Langston JW; Cantor CR; Molinari RJ; Manning-Boğ AB
    Toxicol Lett; 2011 Nov; 207(2):97-103. PubMed ID: 21906664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saffron pre-treatment offers neuroprotection to Nigral and retinal dopaminergic cells of MPTP-Treated mice.
    Purushothuman S; Nandasena C; Peoples CL; El Massri N; Johnstone DM; Mitrofanis J; Stone J
    J Parkinsons Dis; 2013; 3(1):77-83. PubMed ID: 23938314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.
    Sarkar S; Chigurupati S; Raymick J; Mann D; Bowyer JF; Schmitt T; Beger RD; Hanig JP; Schmued LC; Paule MG
    Neurotoxicology; 2014 Sep; 44():250-62. PubMed ID: 25064079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anodal transcranial direct current stimulation prevents methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity by modulating autophagy in an in vivo mouse model of Parkinson's disease.
    Lee SB; Kim HT; Yang HO; Jang W
    Sci Rep; 2018 Oct; 8(1):15165. PubMed ID: 30310174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's disease.
    Revishchin A; Moiseenko L; Kust N; Bazhenova N; Teslia P; Panteleev D; Kovalzon V; Pavlova G
    BMC Neurosci; 2016 Jun; 17(1):34. PubMed ID: 27286696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
    Kim JI; Yang EJ; Lee MS; Kim YS; Huh Y; Cho IH; Kang S; Koh HK
    Int J Neurosci; 2011 Apr; 121(4):209-17. PubMed ID: 21265705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurochemical findings in the MPTP model of Parkinson's disease.
    Schmidt N; Ferger B
    J Neural Transm (Vienna); 2001; 108(11):1263-82. PubMed ID: 11768626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurovascular changes in acute, sub-acute and chronic mouse models of Parkinson's disease.
    Sarkar S; Raymick J; Mann D; Bowyer JF; Hanig JP; Schmued LC; Paule MG; Chigurupati S
    Curr Neurovasc Res; 2014 Feb; 11(1):48-61. PubMed ID: 24274908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.